Streetbeat News

HSCS

Heart Test Laboratories, Inc.

https://heartsciences.com

Industry

Medical - Devices

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Open

2.60

Mkt cap

2.4M

Volume

5.1K

High

2.79

P/E Ratio

-0.32

52-wk high

29.00

Low

2.60

Div yield

N/A

52-wk low

2.36

The article reports on the intraday movements of several healthcare stocks. Notable gainers include NewGenIvf Group, Universe Pharmaceuticals, and Pacific Biosciences, while Perspective Therapeutics, Protagenic Therapeutics, and Regencell Bioscience are among the losers.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 4:31 pm

Maison Solutions Inc. (NASDAQ:MSS) shares surged 91.4% in pre-market trading following a significant year-over-year increase in first-quarter sales. Other notable pre-market movers include Heart Test Laboratories, Inc. (NASDAQ:HSCS), Generations Bancorp NY, Inc. (NASDAQ:GBNY), and BioVie Inc. (NASDAQ:BIVI), among others.

Portfolio Pulse from Avi Kapoor

September 24, 2024 | 9:40 am

Ascendiant Capital has reiterated its Buy rating on Heart Test Laboratories (NASDAQ:HSCS) and maintained a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:41 pm

HeartSciences reported having $4.3 million in cash and cash equivalents and a shareholder's equity of $5.9 million as of July 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 8:19 pm

HeartSciences, an AI-powered medical technology company, has secured $1.9 million in non-dilutive financing, extending its cash runway by $2.4 million. This financial boost comes ahead of its upcoming FDA submissions, providing the company with the opportunity to achieve key commercial milestones.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 1:01 pm

HeartSciences reported that as of April 30, 2024, its cash and cash equivalents were approximately $5.8 million, and shareholders' equity was around $7.3 million.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:29 pm

Heart Test Laboratories, Inc. (HeartSciences) announced an analysis by the Innovation Value Institute on the MyoVista wavECG's potential to improve cardiovascular pathway efficiency. The study suggests that the MyoVista wavECG could significantly reduce the number of LV function test queries, potentially eliminating 49.5% from the waitlist.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 1:08 pm

Heart Test Laboratories' MyoVista wavECG has been selected by the Innovation Value Institute to drive healthcare transformation and will be demonstrated at the 4th Digital Health Symposium at the United Nations General Assembly in September 2024.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:39 pm

The article highlights the pre-market movements of various health care stocks on Wednesday. Significant gainers include ENDRA Life Sciences, Concord Medical Services, and Barinthus Biotherapeutics, while notable losers include SILO Pharma, Cue Health, and Fresh2 Group.

Portfolio Pulse from Benzinga Insights

June 05, 2024 | 12:06 pm

HeartSciences has regained compliance with Nasdaq listing requirements, ensuring its continued presence on the exchange.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 8:19 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.